Drug intelligence / Profile preview

ALM005

Development stage: Preclinical
Lead developer: AlphaMa Biotech
Modality: Small Molecules

Overview

ALM005 is a preclinical-stage small molecule anti-tumor drug candidate discovered using AlphaMa Biotech's artificial intelligence and DNA-encoded library (AI-DEL) platform. In August 2021, AlphaMa Biotech entered into an exclusive license agreement with Simcere Pharmaceuticals, granting Simcere the worldwide rights to develop ALM005 for all indications and commercialize it globally. The specific biological target and mechanism of action of ALM005 have not been publicly disclosed.

Beyond the preview

Go deeper on ALM005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM005.